Top of this page
Skip navigation, go straight to the content

Our Science Dapirolizumab pegol

Clinical Study Information - Dapirolizumab pegol

Disease area
studied
Abbreviated title Phase Study ID Registry database Study results Lay summary Publication (if available)
Systemic Lupus Erythematosus A Phase 2b, randomized, double-blind, PBO-controlled, parallel-group, dose-ranging study followed by an observational period that will evaluate the efficacy of Dapirolizumab Pegol (DZP) in inducing disease control and the safety of DZP in subjects with moderately to severely active Systemic Lupus Erythematosus (SLE) who are receiving standard-of-care medications. Phase 2 SL0023
Completed
NCT02804763
2015-004457-40


LINK
Furie, R. et al. Ann Rheum Dis 2019; 78 (Suppl. 2), p. 775
Systemic Lupus Erythematosus The purpose of this study is to evaluate the ability of dapirolizumab pegol (DZP) as an add-on treatment to standard of care (SOC) medication to achieve clinically relevant long term improvement of moderate to severe disease activity. Phase 3 SL0043
Ongoing